A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)
NCT ID: NCT00000727
Last Updated: 2021-11-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
322 participants
INTERVENTIONAL
1991-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
AZT prolongs survival in patients with AIDS and decreases the occurrence of opportunistic infections such as PCP. However, PCP recurs in about 43 percent of patients receiving AZT, indicating a need for other treatments to reduce the relapse rate.
The two medications to be tested in this study, SMX/TMP and aerosolized PEN, have also been partially effective in preventing recurrence of PCP. It is hoped that the combination of AZT with these medications will be more effective than AZT or one of the medications alone.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The two medications to be tested in this study, SMX/TMP and aerosolized PEN, have also been partially effective in preventing recurrence of PCP. It is hoped that the combination of AZT with these medications will be more effective than AZT or one of the medications alone.
Patients receive the standard dose of AZT at study entry. Low body weight patients receive AZT at a lower dose. Patients are randomly assigned to one of two medications intended to prevent the recurrence of PCP. Patients assigned to SMX/TMP will take 1 capsule which contains both drugs once a day for 1 year. Patients assigned to PEN will have 1 aerosol treatment every 4 weeks for 1 year. Blood will be drawn at intervals in order to estimate blood levels of the drugs and to detect any adverse effects from the drugs. Note: Earlier versions of this protocol reflect its original design as a 3-arm study comparing aerosolized PEN, SMX/TMP, and pyrimethamine-sulfadoxine as secondary prophylaxis of PCP in AIDS patients receiving AZT. In order to reduce the effective sample size and permit the completion of accrual in a reasonable period of time, the pyrimethamine - sulfadoxine arm of this study has been discontinued. Patients randomized to this arm will be continued in this study on the original randomized therapy. Management of these patients will follow that described for SMX/TMP in the latest protocol version. AMENDED: Lower dose of AZT allowed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pentamidine isethionate
Pyrimethamine
Sulfamethoxazole/Trimethoprim
Sulfadoxine/Pyrimethamine
Zidovudine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Randomization within 10 weeks of completing therapy for Pneumocystis carinii pneumonia (PCP).
* Ability to tolerate oral and aerosolized therapy at the time of randomization.
* Life expectancy \> 4 months.
Concurrent Medication:
Allowed:
* Inhaled bronchodilators for cough and bronchospasm related to aerosolized pentamidine treatment.
* Aspirin at modest doses.
* Ibuprofen at modest doses.
* Acetaminophen at modest doses.
* Erythropoietin for management of anemia.
* Allowed to treat opportunistic infections while on study:
* Acyclovir.
* Ketoconazole.
* Amphotericin B.
* Nystatin.
* Clotrimazole.
* Also allowed:
* Ganciclovir (DHPG) for maintenance therapy of life-threatening or sight-threatening cytomegalovirus retinitis (CMV retinitis) infection only.
* Zidovudine (AZT) must be discontinued during the acute induction phase of treatment and will be restarted when maintenance therapy is introduced.
Concurrent Treatment:
Allowed:
* Local radiation therapy for Kaposi's sarcoma.
Prior Medication:
Allowed:
* Primary prophylactic therapy prior to Pneumocystis carinii pneumonia (PCP) episode.
Risk Behavior:
Allowed:
* Patients maintained in a methadone maintenance program per local investigator's judgment.
Exclusion Criteria
Concurrent Medication:
Excluded:
* Famotidine.
* Any medications suspected of interference with the metabolism of zidovudine.
* Flurazepam.
* Chronic probenecid.
* Phenobarbital.
* Phenytoin.
* Experimental therapies, except as noted.
* Chronic oral bronchodilators should not be started in patients in order to maintain them on aerosolized pentamidine after they have exhibited pulmonary toxicity.
Prior Medication:
Excluded for the 30 patients who will undergo pharmacokinetic studies:
* Zidovudine (AZT) at any time.
* Excluded within 7 days of study entry for the 30 patients who will undergo pharmacokinetic studies:
* Trimethoprim / sulfamethoxazole.
* Pyrimethamine / sulfadoxine.
* Aerosolized pentamidine.
* Excluded:
* Pentamidine by any route for the original infection.
* Prophylactic therapy for Pneumocystis carinii pneumonia (PCP) between the discontinuation of acute treatment and study entry.
Prior Treatment:
Excluded within 2 weeks of study entry:
* Transfusions of blood or red blood cells.
Patients may not have any of the following symptoms or diseases:
* Known treatment-limiting hypersensitivity to sulfonamides, trimethoprim, pyrimethamine, pentamidine, or zidovudine (AZT), especially but not limited to, exfoliative dermatitis, erythema multiforme, and Stevens-Johnson syndrome.
* Development of severe hypoglycemia (serum glucose \< 50 mg/dl with pentamidine therapy).
* History of neoplasms other than basal cell carcinoma of the skin or carcinoma in situ of the cervix, or mucocutaneous Kaposi's sarcoma.
* Known visceral Kaposi's sarcoma.
* Known glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Holzman R
Role: STUDY_CHAIR
Hardy WD
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USC CRS
Los Angeles, California, United States
Ucsd, Avrc Crs
San Diego, California, United States
Ucsf Aids Crs
San Francisco, California, United States
Indiana Univ. School of Medicine, Infectious Disease Research Clinic
Indianapolis, Indiana, United States
Bmc Actg Crs
Boston, Massachusetts, United States
University of Minnesota, ACTU
Minneapolis, Minnesota, United States
Memorial Sloan-Kettering Cancer Ctr.
New York, New York, United States
Case CRS
Cleveland, Ohio, United States
University of Washington AIDS CRS
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Freedberg KA, Hardy WD, Holzman RS, Tosteson AN, Craven DE. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Med Decis Making. 1996 Jan-Mar;16(1):29-35. doi: 10.1177/0272989X9601600110.
Hardy WD, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, Frame PT, Holmes M, Waskin H, Fass RJ, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med. 1992 Dec 24;327(26):1842-8. doi: 10.1056/NEJM199212243272604.
Hardy WD, Holzman RS, Avramis V, Bawdon R, Fall H, Feinberg J. Clinical and pharmacokinetic interactions of combined zidovudine (ZDV) therapy and sulfadoxine-pyrimethamine (fansidar) prophylaxis in post-PCP AIDS patients (ACTG 021). Int Conf AIDS. 1989 Jun 4-9;5:294 (abstract no TBP46)
Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000 Sep;56(3):779-88. doi: 10.1111/j.0006-341x.2000.00779.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10997
Identifier Type: REGISTRY
Identifier Source: secondary_id
ACTG 021
Identifier Type: -
Identifier Source: org_study_id